High-dose carmustine for high-grade gliomas in childhood.

Abstract

Carmustine (BCNU) has proved to be of value against a variety of primary brain tumors. This agent exhibits a steep dose-response curve in in vitro and animal tumor models and has been proposed for use in high-dose chemotherapy as a single agent or in combination. We conducted a phase II study to assess high-dose BCNU in children with high-grade gliomas. A total of 13 children with high-grade gliomas were treated in a phase II study using high-dose BCNU (800 mg/m2) followed by autologous bone marrow transplantation. Eight patients were newly diagnosed, and five were treated at the time of tumor recurrence. Seven patients had diffuse intrinsic brain-stem gliomas. The response was assessed at 1 month after treatment. Only one objective effect was observed. Five patients had stable disease and seven progressed. The immediate toxicity was mild; however, one patient developed fatal respiratory distress at 50 days after treatment with high-dose BCNU. Dose escalation of BCNU does not seem beneficial in children with high-grade gliomas.

• Authors: E Bouffet, F Khelfaoui, I Philip, P Biron, M Brunat-Mentigny, T Philip
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 39 Issue 4 Pg. 376-9 ( 1997) ISSN: 0344-5704 [Print] Germany
• PMID: 9025780 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)

Chemical References

• Antineoplastic Agents, Alkylating
• Carmustine

Topics

• Adolescent
• Antineoplastic Agents, Alkylating (administration & dosage)
• Bone Marrow Transplantation
• Brain Neoplasms (drug therapy, therapy)
• Carmustine (administration & dosage)
• Child
• Child, Preschool
• Female
• Glioma (drug therapy, therapy)
• Humans
• Infant
• Male